Suchergebnisse - "Spitaleri, G"

PubPharm (47)

1

Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers

enthalten in: Clinical lung cancer | 2023

von Spitaleri, G. | Trillo Aliaga, P. | Catania, C. | +8

2

Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy

enthalten in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2020

von Passaro, A. | Mancuso, P. | Gandini, S. | +8

ErratumIn: Clin Transl Oncol. 2019 Aug 20;:. - PMID 31432394

3

Correction to : Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy

enthalten in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2020

von Passaro, A. | Mancuso, P. | Gandini, S. | +8

ErratumFor: Clin Transl Oncol. 2020 Apr;22(4):603-611. - PMID 31254252

4

Changes in Pulmonary Function in Patients With Advanced Heart Failure Listed for Heart Transplantation

enthalten in: Transplantation proceedings | 2019

von Domínguez, J. | Keller, B. | Moisés, J. | +5

5

Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy

enthalten in: Clinical & translational oncology | 2019

von Passaro, A. | Mancuso, P. | Gandini, S. | +8

6

Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy

enthalten in: Clinical and translational oncology | 2019

von Passaro, A. | Mancuso, P. | Gandini, S. | +8

7

Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy

enthalten in: Revista de oncología | 2019

von Passaro, A. | Mancuso, P. | Gandini, S. | +8

8

Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy

enthalten in: Clinical & translational oncology | 2019

von Passaro, A. | Mancuso, P. | Gandini, S. | +8

9

Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy

enthalten in: Clinical and translational oncology | 2019

von Passaro, A. | Mancuso, P. | Gandini, S. | +8

10

Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy

enthalten in: Revista de oncología | 2019

von Passaro, A. | Mancuso, P. | Gandini, S. | +8

1
2
3
4
5
Nächster »
[5]